Clinical Trial Update: Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a combination of oncolytic virotherapy, a PD-1 inhibitor, and lenvatinib in advanced pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Oncolytic virotherapy
• PD-1 inhibitor

Snippet

Sponsor: Fudan University | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: COMPLETED